©Viva Biotech (Shanghai) Ltd. 沪ICP备12042930号   Powerd by 

Company News
Totient, a Viva Biotech Portfolio Company, Achieves the Acquisition with AbSci
Intro Remarks:Complementary technologies combined to enable streamlined design and production of next-generation therapeutic proteins for disease-specific targets.
Anji Pharma Launches Phase 3 Trial for ANJ900
To treat type 2 diabetes patients with kidney disease
Viva Biotech Included in the MSCI China Small Index Constituent Stocks
The cradle for biotech companies from all over the world.
Shanghai EPN and BioMap Reached a Strategic Cooperation
To jointly work on the development of autoimmune diseases therapies
TechnoDerma Announced New Progress in Phase I Clinical Trials of TDM-105795 in the U.S.
It is expected that the phase I clinical dose-climbing trial will be completed in about three months.
Page up